UK Bill To Speed Up Post-Brexit Access To Innovative Drugs
Industry Welcomes Move, But Says Detail Lacking
Executive Summary
A new bill giving the UK regulator more powers after Brexit has been welcomed by the life sciences industry. However, observers have warned that it needs fleshing out with detail, and that the government would be wise to proceed carefully if it considers relaxing clinical trial regulations.
You may also be interested in...
Queen’s Speech Promises More NHS Spending After Brexit
The new UK government’s political priorities for the years ahead were laid out in the 19 December Queen’s speech, which inevitably centred around the UK’s departure from the EU next month and the negotiation of a free trade deal with the EU. A rise in NHS spending was promised, and new legislation on the future of medicines regulation is on the horizon.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.